இன்க் ஸ்டாக் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இன்க் ஸ்டாக் பரிமாற்றம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இன்க் ஸ்டாக் பரிமாற்றம் Today - Breaking & Trending Today

Medpace Holdings, Inc. : The underlying trend is in force again


20.83%
Shares in Medpace Holdings, Inc. show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the $ 210.
Summary
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Strengths
Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 67% by 2023.
The group s high margin levels account for strong profits. ....

Medpace Holdings , Inc Stock Exchange , Press Release , Be Medp , இன்க் ஸ்டாக் பரிமாற்றம் , ப்ரெஸ் வெளியீடு ,

Exclusive: GameStop initiates search for new CEO -sources


Message :
Required fields
(Reuters) - GameStop Corp is looking for a new chief executive to replace George Sherman as it pivots from a brick-and-mortar video game retailer to an e-commerce firm, three people familiar with the matter said on Monday.
It would be the biggest shakeup at GameStop since Ryan Cohen, the co-founder and former chief executive of online pet food company Chewy Inc, joined its board in January and began laying the groundwork for a shift in culture and strategy, people familiar with his work at GameStop said.
Its stock is up almost 4,000% from a year ago, after it became the poster child of day traders betting on so-called meme stocks. ....

United States , Elliott Wilke , Matt Francis , Kelli Durkin , Neda Pacifico , Dan Grebler , Matthew Lewis , Frank Hamlin , Jim Bell , Zandrea Wolfe , Jenna Owens , Svea Herbst Bayliss , Ryan Cohen , Home Depot Inc , Chewy Inc , Auto Parts Inc , Chief Financial Officer Jim Bell , Chief Customer Officer Frank Hamlin , Advance Auto Parts Inc , Wall Street , Edward Woo , The Home Depot , Inc Stock Exchange , Press Release , The Hd , ஒன்றுபட்டது மாநிலங்களில் ,

AutoNation, Inc. : Technically solid | MarketScreener


17.98%
The underlying tendency is to the upside for shares in AutoNation, Inc. and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Investors have an opportunity to buy the stock and target the $ 110.
Summary
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
Strengths
The group usually releases upbeat results with huge surprise rates.
The company is one of the most undervalued, with an enterprise value to sales ratio at 0.41 for the 2021 fiscal year. ....

Inc Stock Exchange , Press Release , Come Back , இன்க் ஸ்டாக் பரிமாற்றம் , ப்ரெஸ் வெளியீடு , வாருங்கள் மீண்டும் ,

Lyra Therapeutics : Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual


New data presented includes:
- First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) -
- LYR-210 (7500µg) decreased ethmoid opacification at week 24, a measure of disease modification -
- LYR-210 (7500µg) reduced the need for rescue medication -
- Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achieved statistically significant improvement across 3 cardinal symptoms at week 24 in the LANTERN study -
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2 LANTERN study of LYR-210, the company’s lead long-acting product candidate fo ....

Robert Kern , Anders Cervin , Maria Palasis , Rodney Williams Memorial Foundation , University Of Queensland , Lyra Therapeutics Inc , Lyra Therapeutics , Combined Otolaryngology Spring Meetings , Professor Anders Cervin , Garnett Passe , Rodney Williams Memorial Foundation Chair , Principal Investigator , Oral Presentation , Non Polyp Patients , Cardinal Symptoms , Chief Medical Officer , Chief Executive Officer , Inc Stock Exchange , Press Release , Both Lyra , ராபர்ட் கர்ன் , ரோட்னி வில்லியம்ஸ் நினைவகம் அடித்தளம் , பல்கலைக்கழகம் ஆஃப் குயின்ஸ்லாந்து , லைரா சிகிச்சை இன்க் , லைரா சிகிச்சை , கார்னெட் கடந்த காலம் ,